The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl, MD, University of Toronto, Toronto, Canada, discusses findings from the Phase Ib CHRYSALIS trial (NCT02609776) of amivantamab, an EGFR-MET bispecific antibody, in patients with wild-type non-small cell lung cancer (NSCLC) who have progressed on checkpoint inhibition and chemotherapy. Two cohorts consisting of patients with either adenocarcinomas or squamous lung cancer were recruited, and responses were reported in both cohorts, but patients with KRAS or HER2 mutations did not respond to therapy. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
